600
Participants
Start Date
October 31, 2021
Primary Completion Date
September 30, 2023
Study Completion Date
December 31, 2024
Anti-PD-1 Immune Checkpoint Inhibitors
used as 1st line treatment for metastatic ESCC.
Fudan University Shanghai cancer center, Shanghai
The 2nd affiliated hospital of Bengbu medical University, Bengbu
The 2nd people's hospital of Anhui province, Hefei
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou
The 1st affiliated hospital of Xiamen University, Xiamen
Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center, Shenzhen
The 4th affiliated hospital of Hebei Medical University, Shijiazhuang
Anyang cancer hospital, Anyang
Henan Cancer Hospital, Zhengzhou
Wuhan University Zhongnan hospital, Wuhan
Zhongnan University Xiangya Hospital, Changsha
Huai'an first hospital, Huai'an
Jiangsu cancer Hosipital, Nanjing
Nantong cancer hospital, Nantong
Yancheng the 3rd hospital, Yancheng
The Northern Jiangsu People's Hospital, Yangzhou
Jiangxi Cancer Hospital, Nanchang
The 1st affiliated hospital of Nanchang University, Nanchang
The 2nd affiliated hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Air Force Medical University, Xi'an
Sichuan cancer hospital, Chengdu
Zhejiang Cancer Hospital, Hangzhou
The 2nd affiliated hospital of Wenzhou medical university, Wenzhou
Fudan University
OTHER